Abstract:HomeStrokeVol. 46, No. 4Response to Letter Regarding Article, “Norrin Protected Blood–Brain Barrier via Frizzled-4/β-Catenin Pathway After Subarachnoid Hemorrhage in Rats” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse to Letter Regarding Article, “Norrin Protected Blood–Brain Barrier via Frizzled-4/β-Catenin Pathway After Subarachnoid Hemorrhage in Rats” Yujie Chen, MD and Hua Feng, MD, PhD John H. Zhang, MD, PhD Yujie ChenYujie Chen Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China Search for more papers by this author and Hua FengHua Feng Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China Search for more papers by this author John H. ZhangJohn H. Zhang Department of Physiology and Pharmacology, Loma Linda University, CA Search for more papers by this author Originally published26 Feb 2015https://doi.org/10.1161/STROKEAHA.115.008779Stroke. 2015;46:e91Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2015: Previous Version 1 We appreciate Zuo and Xu1 for their interest in our study and their concerns about the frizzled-4 small interfering RNA (siRNA) efficacy in our experiments. We concur that the magnitude of suppression of siRNA in vivo was less than that achieved in vitro, therefore we used a pool of 3 different frizzled-4 siRNA duplexes to improve the knockdown efficiency. As presented in Figure IV in the online-only Data Supplement,2 frizzled-4 siRNA pretreatment significantly inhibited frizzled-4 receptor expression in ipsilateral hemisphere 48 hours after intraventricular siRNA injection. The average protein level of frizzled-4 was reduced ≈50% by siRNA than scrambled siRNA. Most importantly, the frizzled-4 siRNA did reverse its ligand norrin’s neuroprotective effects on blood–brain barrier integrity and early brain injury after subarachnoid hemorrhage.Furthermore, we investigated the possible mechanism of how norrin performed these protective effects on blood–brain barrier and neurological functions and found norrin acted via frizzled-4/β-catenin pathway to enhance the expressions of tight junction proteins zona occludens (ZO)-1, occludin and adherent junction protein vascular endothelial-cadherin.2 However, Zuo and Xu, with reliable speculation, proposed that norrin/frizzled-4/β-catenin pathway could also enhance the expression of gap junction protein connexin-43. Although Connexin-43 is colocalized and coprecipitated with several tight junction proteins, it mainly forms ion channels and allows intercellular trafficking of ions and small signaling molecules through perivascular astrocyte networks. Nagasawa et al3 demonstrated that blocking gap junction did not influence the expression of occludin, claudin-5, ZO-1, or their subcellular localization in the blood–brain barrier endothelial cells. With connexin-43 knockout condition, even astrocyte end-feet enlarged, the endothelial cells were structurally normal in appearance, including their tight junctions, which was only vulnerable when subjected to elevated hydrostatic pressure and sheer stress.4 In addition, claudin-5, occludin, and vascular endothelial-cadherin recovered from the second day after blood nerve barrier injury, whereas connexin-43 was redetected on the fifth day.5 These results indicate that norrin/frizzled-4/β-catenin pathway could preserve tight junction proteins and adherent junction proteins in the early phase after subarachnoid hemorrhage to repair the mechanical barrier of blood–brain barrier and alleviate early brain injury.Currently, most efforts on the blood–brain barrier and brain edema focus on vasogenic edema after subarachnoid hemorrhage6; Drs Zuo and Xu raised the potential cytotoxic edema in their letter, which is an extremely important question; however, cytotoxic edema is mostly verified by an MRI and which is not in the scope of our published study. But we agree with Drs Zuo and Xu that cytotoxic edema needs to be studied in similar experimental conditions after subarachnoid hemorrhage.Yujie Chen, MDHua Feng, MD, PhDDepartment of Neurosurgery, Southwest HospitalThird Military Medical UniversityChongqing, ChinaJohn H. Zhang, MD, PhDDepartment of Physiology and PharmacologyLoma Linda UniversityCASources of FundingThis study is supported by a grant from National Institutes of HealthNS081740 to Dr Zhang.DisclosuresNone.FootnotesStroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 3 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited.References1. Zuo X, Xu E.Letter by Zuo and Xu regarding article, “Norrin protected blood–brain barrier via frizzled-4/β-catenin pathway after subarachnoid hemorrhage in rats.”Stroke. 2015; 46:e90. doi: 10.1161/STROKEAHA.115.008770.LinkGoogle Scholar2. Chen Y, Zhang Y, Tang J, Liu F, Hu Q, Luo C, et al. Norrin protected blood–brain barrier via frizzled-4/β-catenin pathway after subarachnoid hemorrhage in rats.Stroke. 2015; 46:529–536. doi: 10.1161/STROKEAHA.114.007265.LinkGoogle Scholar3. Nagasawa K, Chiba H, Fujita H, Kojima T, Saito T, Endo T, et al. Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells.J Cell Physiol. 2006; 208:123–132. doi: 10.1002/jcp.20647.CrossrefMedlineGoogle Scholar4. Ezan P, André P, Cisternino S, Saubaméa B, Boulay AC, Doutremer S, et al. Deletion of astroglial connexins weakens the blood-brain barrier.J Cereb Blood Flow Metab. 2012; 32:1457–1467. doi: 10.1038/jcbfm.2012.45.CrossrefMedlineGoogle Scholar5. Hirakawa H, Okajima S, Nagaoka T, Takamatsu T, Oyamada M.Loss and recovery of the blood-nerve barrier in the rat sciatic nerve after crush injury are associated with expression of intercellular junctional proteins.Exp Cell Res. 2003; 284:196–210.CrossrefMedlineGoogle Scholar6. Chen S, Feng H, Sherchan P, Klebe D, Zhao G, Sun X, et al. Controversies and evolving new mechanisms in subarachnoid hemorrhage.Prog Neurobiol. 2014; 115:64–91. doi: 10.1016/j.pneurobio.2013.09.002.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Yan H, Chen Y, Li L, Jiang J, Wu G, Zuo Y, Zhang J, Feng H, Yan X and Liu F (2016) Decorin alleviated chronic hydrocephalus via inhibiting TGF-β1/Smad/CTGF pathway after subarachnoid hemorrhage in rats, Brain Research, 10.1016/j.brainres.2015.11.004, 1630, (241-253), Online publication date: 1-Jan-2016. April 2015Vol 46, Issue 4 Advertisement Article InformationMetrics © 2015 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.115.008779PMID: 25721016 Originally publishedFebruary 26, 2015 PDF download Advertisement SubjectsAnimal Models of Human Disease

Abstract:HomeCirculationVol. 147, No. 4Letter by Gutmann et al Regarding Article, "Circulating MicroRNA-122-5p Is Associated With a Lack of Improvement in Left Ventricular Function After Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellular Vesicles" Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Gutmann et al Regarding Article, "Circulating MicroRNA-122-5p Is Associated With a Lack of Improvement in Left Ventricular Function After Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellular Vesicles" Clemens Gutmann, Stefan Stojkovic and Manuel Mayr Clemens GutmannClemens Gutmann https://orcid.org/0000-0003-0675-8632 King's College London, School of Cardiovascular and Metabolic Medicine and Sciences, United Kingdom (C.G., M.M.). Department of Cardiology, Innere Medizin II, Medical University Vienna, Austria (C.G., S.S., M.M). , Stefan StojkovicStefan Stojkovic Department of Cardiology, Innere Medizin II, Medical University Vienna, Austria (C.G., S.S., M.M). and Manuel MayrManuel Mayr https://orcid.org/0000-0002-0597-829X King's College London, School of Cardiovascular and Metabolic Medicine and Sciences, United Kingdom (C.G., M.M.). Department of Cardiology, Innere Medizin II, Medical University Vienna, Austria (C.G., S.S., M.M). Originally published23 Jan 2023https://doi.org/10.1161/CIRCULATIONAHA.122.062334Circulation. 2023;147:e68–e69To the Editor:We have read the study by Hosen et al1 with great interest and deem the finding that circulating microRNA-122 (miR-122) is associated with a lack of improvement in left ventricular function after transcatheter aortic valve replacement of substantial clinical relevance. However, we advise caution regarding the interpretation that miR-122 is carried by endothelial cell (EC)–derived extracellular vesicles and that miR-122 levels within extracellular vesicles are sufficiently high to affect cardiomyocyte function in vivo through horizontal miRNA transfer. Instead, we argue that circulating miR-122 is a marker of hepatic congestion attributable to increased central venous pressure in heart failure.MiR-122 represents a well-characterized miRNA, which has been found to be highly expressed in the liver,2 where its transcription is controlled by hepatocyte nuclear factor 4 alpha.3 MiR-122 accounts for >70% of miRNA expression in the liver, and non-human primate models have shown a regulatory role in cholesterol and fatty acid metabolism.4 Hepatic miR-122 is constantly secreted into the circulation, where it ranks among the most readily detectable miRNAs, with levels increasing further on liver injury.4 Therefore, circulating miR-122 levels correlate strongly with hepatic miR-122 expression, as well as conventional liver parameters measured in blood such as alanine and aspartate aminotransferases.4 Moreover, miR-122 has previously been associated with both right and left ventricular dysfunction and with adverse outcome in patients with heart failure with reduced ejection fraction. An increase in miR-122 predates overt liver failure and might indicate beginning liver injury attributable to hepatic congestion.5Hosen et al1 have investigated left ventricular dysfunction. Although isolated left-sided heart failure predominantly affects the lungs with minor effects on central venous pressure, information on right ventricular function, central venous pressure, or liver parameters is not included in the article. Given that the focus of the article is on the most severely affected patients after transcatheter aortic valve replacement, one can assume that hepatic miR-122 release attributable to hepatic congestion represents the primary source of variation.Regarding the in vitro data, a likely source of miR-122 in cell cultures is fetal calf or bovine serum. The authors report miR-122 expression in ECs and cardiomyocytes, but it remains unclear how many copy numbers were detected per cell and how abundant miR-122 was compared with other well-characterized ECs or cardiomyocyte miRNAs. Moreover, in vitro models with donor cells overexpressing candidate miRNAs that are then detected in cocultured recipient cells are not proof that horizontal miRNA transfer exists in vivo at relevant levels. Likewise, the authors did not investigate whether modulation of miR-122 levels affects cardiac function in vivo.In summary, we deem the finding that miR-122 is associated with a lack of improvement in left ventricular function after transcatheter aortic valve replacement of great interest. It expands on our previous finding of elevated miR-122 in patients with chronic systolic heart failure.5 However, we disagree with the interpretation that lack of improvement in cardiac function after transcatheter aortic valve replacement is explained by shuttling of EC-derived miR-122 to cardiomyocytes. MiR-122 has exquisite tissue specificity, and circulating miR-122 levels are determined by hepatic secretion, not by EC-derived extracellular vesicles.FootnotesCirculation is available at www.ahajournals.org/journal/circREFERENCES1. Hosen MR, Goody PR, Zietzer A, Xiang X, Niepmann ST, Sedaghat A, Tiyerili V, Chennupati R, Moore JB, Boon RA, et al. Circulating microRNA-122-5p is associated with a lack of improvement in left ventricular function after transcatheter aortic valve replacement and regulates viability of cardiomyocytes through extracellular vesicles.Circulation. 2022; 146:1836–1854. doi: 10.1161/CIRCULATIONAHA.122.060258LinkGoogle Scholar2. Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stähler C, Meese E, et al. Distribution of miRNA expression across human tissues.Nucleic Acids Res. 2016; 44:3865–3877. doi: 10.1093/nar/gkw116CrossrefMedlineGoogle Scholar3. Li Z-Y, Xi Y, Zhu W-N, Zeng C, Zhang Z-Q, Guo Z-C, Hao D-L, Liu G, Feng L, Chen H-Z, et al. Positive regulation of hepatic miR-122 expression by HNF4α.J Hepatol. 2011; 55:602–611. doi: 10.1016/j.jhep.2010.12.023CrossrefMedlineGoogle Scholar4. Willeit P, Skroblin P, Kiechl S, Fernández-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?.Eur Heart J. 2016; 37:3260–3266. doi: 10.1093/eurheartj/ehw146CrossrefMedlineGoogle Scholar5. Stojkovic S, Koller L, Sulzgruber P, Hülsmann M, Huber K, Mayr M, Hengstenberg C, Wojta J, Niessner A. Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure.Int J Cardiol. 2020; 303:80–85. doi: 10.1016/j.ijcard.2019.11.090CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails January 24, 2023Vol 147, Issue 4 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.122.062334PMID: 36689571 Originally publishedJanuary 23, 2023 PDF download Advertisement SubjectsCatheter-Based Coronary and Valvular InterventionsValvular Heart Disease

Letter by Gao and Shao Regarding Article, "Microrna-126-3p/-5p Overexpression Attenuates Blood-Brain Barrier Disruption in a Mouse Model of Middle Cerebral Artery Occlusion".

Foxo1-induced Mir-92B Down-Regulation Promotes Blood-Brain Barrier Damage after Ischaemic Stroke by Targeting NOX4

Letter by Zuo and Xu Regarding Article, “norrin Protected Blood–Brain Barrier Via Frizzled-4/β-Catenin Pathway after Subarachnoid Hemorrhage in Rats”

Silencing of microRNA-494 inhibits the neurotoxic Th1 shift via regulating HDAC2-STAT4 cascade in ischaemic stroke

ISDN2014_0330: Activation of T‐LAK‐cell‐originated Protein Kinase Contribute to the Anti‐oxidative Function Against Focal Cerebral Ischemia‐reperfusion

MicroRNA-193a-5p Rescues Ischemic Cerebral Injury by Restoring N2-Like Neutrophil Subsets

The evolution of blood–brain barrier permeability changes after stroke and its implications on clinical outcome: A systematic review and meta-analysis

Massive Microbleeds in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy

MicroRNA-132 Attenuates Cerebral Injury by Protecting Blood-Brain-barrier in MCAO Mice

Letter by Chen Et Al Regarding Article, “Five-Year Risk of Major Ischemic and Hemorrhagic Events after Intracerebral Hemorrhage”

Arterialized Vein Immediately after Direct Bypass Surgery Indicates Cerebral Hyperperfusion Syndrome in Moyamoya Disease.

MiRNA-424 Protects Against Permanent Focal Cerebral Ischemia Injury in Mice Involving Suppressing Microglia Activation

Letter by Li Et Al Regarding Article, “circulating MicroRNA-122-5p is Associated with a Lack of Improvement in Left Ventricular Function after Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellular Vesicles”

miR-98 reduces endothelial dysfunction by protecting blood–brain barrier (BBB) and improves neurological outcomes in mouse ischemia/reperfusion stroke model

Response to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China”

Role of microRNA-34a in blood–brain barrier permeability and mitochondrial function in ischemic stroke

Abstract TP252: MicroRNA-376a-5p Improves Outcome for Acute Ischemic Stroke after Endovascular Mechanical Reperfusion in Rat Model

Letter by Wu Et Al Regarding Article, “Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis”

Letter by Zhang Et Al Regarding Article, "hypotension During Endovascular Treatment of Ischemic Stroke is A Risk Factor for Poor Neurological Outcome"

miR-671-5p Upregulation Attenuates Blood–Brain Barrier Disruption in the Ischemia Stroke Model Via the NF-кB/MMP-9 Signaling Pathway

AIM2 Deletion Enhances Blood‐brain Barrier Integrity in Experimental Ischemic Stroke